Rossari Biotech Ltd

AI
Rossari Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Rossari Biotech Ltd

₹ 417 -4.71%
21 Oct - close price
rossari.com BSE: 543213 NSE: ROSSARI
About

Rossari Biotech was started in 2003.
They are among the largest manufacturers
of textile specialty chemicals in India.[1]

Key Points

Product Segments:[1]
The company is one of India’s leading specialty chemicals manufacturer offering 4,280+ products across 3 verticals:

Website BSE NSE
  • Market Cap ₹ 2,305 Cr.
  • Current Price ₹ 417
  • High / Low ₹ 663 / 373
  • Stock P/E 15.0
  • Book Value ₹ 232
  • Dividend Yield 0.12 %
  • ROCE 14.8 %
  • ROE 11.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 11.0% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE Commodities BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
332 299 314 301 336 368 427 366 420 451 516 482 495
290 258 272 261 292 318 374 322 369 400 453 426 438
Operating Profit 42 41 42 40 44 50 52 44 50 50 64 56 57
OPM % 13% 14% 13% 13% 13% 14% 12% 12% 12% 11% 12% 12% 12%
2 2 1 1 1 1 2 2 1 1 23 2 2
Interest 3 3 2 2 2 2 3 3 2 4 4 4 2
Depreciation 6 6 7 6 7 7 8 7 7 7 9 8 11
Profit before tax 36 35 35 33 37 41 44 35 42 40 74 46 46
Tax % 26% 27% 25% 26% 26% 26% 26% 26% 26% 24% 26% 26% 26%
26 26 26 24 27 31 32 26 31 31 55 34 34
EPS in Rs 4.78 4.62 4.74 4.40 4.96 5.53 5.84 4.74 5.64 5.53 9.88 6.19 6.18
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
122 178 233 292 516 600 690 1,073 975 1,203 1,432 1,752 1,944
108 166 209 247 438 495 569 950 853 1,042 1,245 1,544 1,717
Operating Profit 13 12 24 45 78 105 121 123 123 161 186 208 228
OPM % 11% 7% 10% 15% 15% 18% 18% 11% 13% 13% 13% 12% 12%
0 0 1 1 1 4 10 13 4 7 6 27 28
Interest 3 3 2 1 3 4 3 3 5 10 10 13 14
Depreciation 5 4 4 5 12 17 22 26 26 24 28 31 36
Profit before tax 6 5 19 39 63 88 106 107 96 134 155 191 206
Tax % 11% 29% 17% 27% 28% 26% 25% 26% 25% 26% 26% 25%
5 3 16 29 46 66 79 79 71 100 115 143 154
EPS in Rs 1.05 0.71 3.22 5.98 9.46 12.91 15.23 14.43 12.94 18.04 20.72 25.79 27.78
Dividend Payout % 1% 0% 1% 0% 0% 4% 3% 3% 4% 3% 2% 2%
Compounded Sales Growth
10 Years: 26%
5 Years: 20%
3 Years: 22%
TTM: 23%
Compounded Profit Growth
10 Years: 44%
5 Years: 10%
3 Years: 22%
TTM: 28%
Stock Price CAGR
10 Years: %
5 Years: -22%
3 Years: -20%
1 Year: -36%
Return on Equity
10 Years: 14%
5 Years: 11%
3 Years: 11%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 4 4 4 4 4 10 10 11 11 11 11 11 11
Reserves 27 41 56 85 116 273 394 774 848 949 1,066 1,207 1,275
38 22 24 22 9 67 0 0 65 68 50 144 101
24 37 37 49 119 118 140 141 202 253 324 401 412
Total Liabilities 93 104 122 160 248 468 544 926 1,126 1,281 1,451 1,764 1,799
43 36 37 44 74 94 171 177 157 167 179 218 255
CWIP 0 8 8 10 3 22 0 1 14 25 34 105 79
Investments 0 0 0 3 0 15 9 381 493 528 538 548 543
50 60 77 103 171 338 364 367 462 561 699 893 923
Total Assets 93 104 122 160 248 468 544 926 1,126 1,281 1,451 1,764 1,799

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 23 2 22 72 56 52 33 113 74 92 59
0 -5 -6 -16 -41 -187 -37 -318 -160 -70 -70 -102
0 -18 3 -6 -26 155 -29 297 61 -22 -32 79
Net Cash Flow 0 1 -0 -1 5 23 -14 12 14 -18 -10 36
Free Cash Flow 0 19 -3 8 28 -20 -4 3 92 24 39 -36
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 0% 202% 22% 72% 118% 72% 68% 47% 112% 68% 71% 53%

Ratios

Standalone / View Consolidated

Mar 2011 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 70 59 74 75 61 57 73 62 91 92 96 108
Inventory Days 77 70 52 65 59 57 72 48 58 61 62 50
Days Payable 83 79 70 71 114 95 100 52 92 92 100 102
Cash Conversion Cycle 63 50 56 69 6 19 44 58 58 61 58 56
Working Capital Days 78 11 23 42 20 22 61 63 52 67 72 61
ROCE % 27% 42% 55% 38% 29% 18% 12% 14% 15% 15%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Installed Capacity
MTPA

Log in to view insights

Please log in to see hidden values.

Login
Number of Customers
customers
Number of Countries Exported To
countries
Number of Products
products
Export Revenue
Rs. crore
AHN Segment Revenue
Rs. crore
HPPC Segment Revenue
Rs. crore
TSC Segment Revenue
Rs. crore

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
68.34% 68.32% 68.32% 68.27% 68.19% 68.18% 68.18% 68.18% 68.15% 68.15% 68.14% 68.14%
4.14% 4.02% 3.83% 3.74% 3.74% 3.98% 3.48% 2.70% 2.32% 2.18% 2.03% 1.84%
18.06% 17.74% 16.87% 17.34% 17.47% 17.59% 17.84% 18.18% 18.25% 18.21% 14.64% 14.19%
9.45% 9.90% 10.98% 10.64% 10.60% 10.24% 10.50% 10.95% 11.25% 11.46% 15.19% 15.84%
No. of Shareholders 1,00,42398,8591,00,47597,18895,73592,85291,79191,38789,24986,97287,58086,622

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls